公开(公告)号：US20090010934A1

公开(公告)日：2009-01-08

申请号：US11963687

申请日：2007-12-21

申请人： Hans Deckmyn ,  Nancy Cauwenberghs

发明人： Hans Deckmyn ,  Nancy Cauwenberghs

IPC分类号： A61K39/395 ,  A61P7/00

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K2317/55 ,  C07K2317/76

摘要： A ligand derived from, e.g., a Fab fragment of a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-Organisms under accession number LMBP 5108CB binds to the human platelet glycoprotein GPIb and prevents the binding of von Willebrand factor to said GPIb without inducing thrombocytopenia. The said ligand is useful, in admixture with a pharmaceutically acceptable carrier, in a pharmaceutical composition, optionally further comprising a thrombolytic agent, for preventing and/or treating haemostasis disorders.

摘要翻译： 衍生自例如可从保藏号为LMBP 5108CB的比利时微生物协调收集物的细胞系获得的单克隆抗体的Fab片段的配体结合人血小板糖蛋白GPIb并防止血管性血友病因子与 说GPIb不引起血小板减少症。 所述配体在药学上可接受的载体的混合物中可用于药物组合物中，任选地还包含溶栓剂，用于预防和/或治疗止血障碍。

公开(公告)号：US20100099202A1

公开(公告)日：2010-04-22

申请号：US12620097

申请日：2009-11-17

申请人： Nancy Cauwenberghs ,  Karen Vanhoorelbeke ,  Hans Deckmyn

发明人： Nancy Cauwenberghs ,  Karen Vanhoorelbeke ,  Hans Deckmyn

IPC分类号： G01N33/543

CPC分类号： G01N33/86 ,  G01N2333/755 ,  Y10S436/805 ,  Y10S436/819

摘要： The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(α) (GPIb(α)) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(α), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(α) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.

摘要翻译： 本发明涉及一种检测血管性血友病因子（vWF）活性的方法，包括在糖蛋白Ib（α）（GPIb（α））和瑞斯他汀的可溶形式或部分存在下测定样品或功能等同物质 。 此外，本发明涉及上述可溶形式或部分糖蛋白Ib（α），瑞斯托菌素或功能等同物质，特异性地使抗GPIB（α）抗体和/或特异性结合配偶体 ，特异性地使抗vWF抗体与本发明的方法进行反应。 此外，本发明涉及用于实施本发明的方法的试剂盒。

公开(公告)号：US07622259B1

公开(公告)日：2009-11-24

申请号：US10019740

申请日：2000-07-05

申请人： Nancy Cauwenberghs ,  Karen Vanhoorelbeke ,  Hans Deckmyn

发明人： Nancy Cauwenberghs ,  Karen Vanhoorelbeke ,  Hans Deckmyn

IPC分类号： G01N33/53 ,  G01N33/60 ,  G01N33/536 ,  G01N33/541 ,  G01N33/543 ,  G01N33/552 ,  G01N33/566 ,  G01N33/577 ,  G01N21/75 ,  G01N21/76 ,  G01N21/78

CPC分类号： G01N33/86 ,  G01N2333/755 ,  Y10S436/805 ,  Y10S436/819

摘要： The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(α) (GPIb(α) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(α), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(α) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.

摘要翻译： 本发明涉及一种用于检测血管性血友病因子（vWF）活性的方法，包括在糖蛋白Ib（α）（GPIb（α）和瑞斯托菌素）或功能等同物质的可溶形式或部分存在下测定样品。 另外，本发明涉及前述的抗GPIB（α）抗体和/或特异性结合配偶体特异性反应的上述可溶形式或部分糖蛋白Ib（α），瑞斯托菌素或功能等同物质的用途 ，特别是使抗vWF抗体特异性地与本发明的方法进行反应，而且本发明涉及用于实施本发明方法的试剂盒。

公开(公告)号：US07754215B2

公开(公告)日：2010-07-13

申请号：US11612257

申请日：2006-12-18

申请人： Hans Deckmyn ,  Nancy Cauwenberghs ,  Karen Vanhoorelbeke

发明人： Hans Deckmyn ,  Nancy Cauwenberghs ,  Karen Vanhoorelbeke

IPC分类号： A61K39/395

CPC分类号： C07K16/36 ,  A61K2039/505 ,  C07K2317/55

摘要： The present invention clearly demonstrates that vWF-collagen interaction, via the A3 domain of vWF, plays an important role in acute platelet-dependent arterial thrombus formation and that blocking the A3 domain in a vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, an antibody or an antigen recognizing fragment thereof binding specifically to the A3 domain of vWF or an epitope thereof can be used for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to for the prevention of acute arterial thrombotic syndromes.

摘要翻译： 本发明清楚地表明，通过vWF的A3结构域的vWF-胶原相互作用在急性血小板依赖性动脉血栓形成中起重要作用，并且在vWF-胶原相互作用中阻断A3结构域可诱导完全消除血栓形成 受伤和狭窄的狒狒股动脉。 因此，与vWF的A3结构域或其表位特异性结合的抗体或其抗原识别片段可用于预防急性动脉血栓形成综合征或制造用于预防急性动脉血栓形成综合征的药物。

公开(公告)号：US07332162B1

公开(公告)日：2008-02-19

申请号：US10049868

申请日：2000-08-08

申请人： Hans Deckmyn ,  Nancy Cauwenberghs

发明人： Hans Deckmyn ,  Nancy Cauwenberghs

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K2317/55 ,  C07K2317/76

摘要： A ligand derived from, e.g. a Fab fragment of, a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-organisms under accession number LMBP 5108CB binds to the human platelet glycoprotein GPib and prevents the binding of von Willebrand factor to said GPIb without inducing thrombocytopenia. The said ligand is useful, in admixture with a pharmaceutically acceptable carrier, in a pharmaceutical composition, optionally further comprising a thrombolytic agent, for preventing and/or treating haemostasis disorders.

摘要翻译： 衍生自例如 从保藏号为LMBP 5108CB的比利时微生物协调收集物的细胞系获得的单克隆抗体的Fab片段与人血小板糖蛋白GPib结合并防止血管性血友病因子与所述GPIb结合而不诱导血小板减少症。 所述配体在药学上可接受的载体的混合物中可用于药物组合物中，任选地还包含溶栓剂，用于预防和/或治疗止血障碍。

公开(公告)号：US20090311267A1

公开(公告)日：2009-12-17

申请号：US12383315

申请日：2009-03-23

申请人： Guido Stoll ,  Christoph Kleinschnitz ,  Bernhard Nieswandt ,  Hans Deckmyn ,  Simon De Meyer

发明人： Guido Stoll ,  Christoph Kleinschnitz ,  Bernhard Nieswandt ,  Hans Deckmyn ,  Simon De Meyer

IPC分类号： A61K39/395

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76

摘要： The invention relates generally to an anti-thrombotic treatment of occlusive syndromes in the cerebral vascular system causing cerebral infarct due to stroke or ischemic stroke, which is a major cause of death and permanent disability in industrialized countries. More particularly, the invention relates to a system and method of preventing and treating such occlusive syndromes in the cerebral vascular by inhibiting initial adhesion/attachment of platelets to the endothelium by preventing or inhibiting binding of von Willebrand factor to platelet glycoprotein Ib by administration of a subject in such need anti-glycoprotein Ib monovalent antibodies and/or anti-vWF monovalent antibodies, rather than by blocking the common pathway of platelet aggregation by blockade of platelet aggregation with anti-glycoprotein IIb/IIIa.

摘要翻译： 本发明一般涉及脑血管系统中由于卒中或缺血性卒中导致脑梗塞的闭塞综合征的抗血栓形成治疗，这是工业化国家死亡和永久性残疾的主要原因。 更具体地说，本发明涉及一种通过预防或抑制血管性血友病因子与血小板糖蛋白Ib的结合来抑制血小板初始粘附/附着至内皮的预防和治疗脑血管闭塞综合征的系统和方法， 需要抗糖蛋白Ib单价抗体和/或抗vWF单价抗体，而不是通过阻断与抗糖蛋白IIb / IIIa的血小板聚集来阻断血小板聚集的共同途径。